Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

ClinicalTrials.gov ID: NCT02267083

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02267083. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.

Study identification

NCT ID: NCT02267083
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Gem Pharmaceuticals; Industry
Enrollment: 22 participants

Conditions and interventions

Conditions

Soft Tissue Sarcoma

Interventions

GPX-150 for Injection Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 7, 2015 (Type not available)
Primary completion: Nov 11, 2015 (Actual)
Completion: Aug 18, 2016 (Actual)
Last update posted: Jan 10, 2018

2015 – 2016

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
Northwestern University	Chicago	Illinois	60611	—
University of Iowa Holden Comprehensive Cancer Center	Iowa City	Iowa	52242	—
Washington University School of Medicine	St Louis	Missouri	63110	—
Penn State Milton S Hershey Medical Center	Hershey	Pennsylvania	17033	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02267083, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 10, 2018 · Synced Nov 12, 2026